文献速递垂体与肾上腺疾病性腺与生殖内分泌

脉冲式促性腺激素释放激素治疗可能恢复先天性联合性垂体激素缺乏症患者的下丘脑-垂体-睾丸轴功能:一项前瞻性自身对照试验

Pulsatile GnRH Therapy May Restore Hypothalamus-Pituitary-Testis Axis Function in Patients With Congenital Combined Pituitary Hormone Deficiency: A Prospective, Self-Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项前瞻性自身对照3个月临床试验在40例先天性联合性垂体激素缺乏症(CCPHD)男性患者中评估脉冲式促性腺激素释放激素(GnRH)治疗对垂体的反应。60%(24/40)患者反应良好,黄体生成素(LH)和卵泡刺激素(FSH)升至正常范围,睾酮升至8.67 ± 4.83 nmol/L,其中33.3%(8/24)实现精子生成;磁共振成像(MRI)未显示垂体反应与垂体高度和/或垂体柄完整性相关。作者认为该结果可能直接指导临床治疗选择。

要点

  • 40例CCPHD男性完成3个月脉冲式GnRH治疗,60%(24/40)反应良好。
  • 反应组LH和FSH升至正常范围,睾酮升至8.67 ± 4.83 nmol/L。
  • 反应组33.3%(8/24)实现精子生成,MRI未显示垂体反应与垂体高度和/或垂体柄完整性相关。

核心结论

  • 作者认为CCPHD患者的促性腺激素细胞可以存在并具有功能,即使MRI显示垂体发育不良或发育异常。
  • 脉冲式GnRH治疗使60%(24/40)CCPHD患者的垂体-睾丸轴功能恢复。
  • 作者认为这些结果可能直接指导临床治疗选择。

研究设计与样本

  • 前瞻性自身对照3个月临床试验,在大学内分泌门诊开展。
  • 研究对象为CCPHD所致低促性腺激素性性腺功能减退症男性患者,共40例完成研究。
  • 干预为皮下给予脉冲式GnRH,持续3个月。
  • 主要终点为总血清睾酮、睾丸体积、LH和FSH水平,次要终点包括精子生成的发生。

主要发现

  • 60%(24/40)患者对脉冲式GnRH治疗反应良好(反应组),其余40%(16/40)反应不佳。
  • 反应组在3个月时LH和FSH水平升至正常范围,睾酮水平升至8.67 ± 4.83 nmol/L。
  • 反应组中33.3%(8/24)患者实现精子生成。
  • MRI未显示垂体反应与垂体高度和/或垂体柄完整性之间存在任何相关性。

关键数值与推荐

  • 反应良好定义为对脉冲式GnRH治疗反应良好(反应组),占60%(24/40)。
  • 反应组3个月时睾酮水平为8.67 ± 4.83 nmol/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The effectiveness of pulsatile gonadotropin-releasing hormone (GnRH) therapy in patients with congenital combined pituitary hormone deficiency (CCPHD) has not been investigated because of the limited number of patients, as well as these patients' presumed pituitary hypoplasia, poor gonadotrophic cell reserve, and impaired gonadotrophic response to GnRH. OBJECTIVE: To assess the pituitary response to pulsatile GnRH therapy in men with CCPHD. DESIGN: Prospective, self-controlled, 3-month clinical trial. SETTINGS: University endocrine clinic. PATIENTS: Men with hypogonadotropic hypogonadism caused by CCPHD. INTERVENTION: Pulsatile GnRH was administered subcutaneously for 3 months. MAIN OUTCOME MEASURES: Primary endpoints were total serum testosterone, testicular volume, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. Secondary endpoints included occurrence of spermatogenesis. RESULTS: A total of 40 men with CCPHD completed the study. Of these, 60% (24 of 40) showed a good response to pulsatile GnRH treatment (response group). At 3 months, their LH and FSH levels increased to within the normal range and their testosterone levels increased to 8.67 ± 4.83 nmol/L. Of the patients in the response group, 33.3% (8 of 24) of them achieved spermatogenesis. The remaining 40% (16 of 40) of patients had a poor response to pulsatile GnRH treatment. Magnetic resonance imaging (MRI) did not reveal any correlation between pituitary response and pituitary height and/or integrity of the pituitary stalk. CONCLUSIONS: This study suggests that gonadotrophs in patients with CCPHD can exist and be functional-even with MRI evidence of pituitary hypoplasia or dysplasia. Pulsatile GnRH therapy restored pituitary-testis axis function in 60% of patients with CCPHD. These results may directly guide the clinical therapeutic choice.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zheng J, Mao J, Xu H, et al. Pulsatile GnRH Therapy May Restore Hypothalamus-Pituitary-Testis Axis Function in Patients With Congenital Combined Pituitary Hormone Deficiency: A Prospective, Self-Controlled Trial. J Clin Endocrinol Metab. 2017. PMID: 28368486. doi:10.1210/jc.2016-3990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。